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Available online 11 February 2016The Genea021 human embryonic stem cell line was derived from a donated, fully commercially consented ART
blastocyst, carrying Trisomy 21, indicative of Down Syndrome. Following ICM outgrowth on inactivated
human feeders, CGH and STR analyses demonstrated a 47, XY, +21 karyotype and male allele pattern. The
hESC line had pluripotent cell morphology, 71% of cells expressed Nanog, 84% Oct4, 23% Tra1–60 and 95%
SSEA4, gave a Pluritest Pluripotency score of 21.85, Novelty of 1.42, demonstrated Alkaline Phosphatase activity
and tri-lineage teratoma formation. The cell line was negative for Mycoplasma and visible contamination.
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Cell line derivation
The fresh, blastocyst stage embryo was plated whole onto Mitomy-
cin C inactivated human feeders (Detroit 551 HFF — 130,000/well in
4-well) in 20% KSR medium with (Amit et al., 2000) with 50 ng/ml
FGF added fresh. CGH karyotyping and STR proﬁling were performed
at the ﬁrst cryobanking step from ICM outgrowths maintained on
feeders. Alkaline Phosphatase staining and teratoma formation were
performed from feeders. Cells were then enzymatically passaged as sin-
gle cells in M2 pluripotent cell maintenance medium (Genea Biocells)
and CGH/karyotyping repeated, immunoﬂuorescent pluripotentmarker
staining, Pluritest and sterility testing performed.tp://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1.Morphology and karyotype of Genea021. A) Alkaline phosphatase activity (passage
14) on human inactivated feeders. B) Karyotypic analysis (passage 44, 2 enzymatic)
showing 47, XY, +21, Trisomy 21 affected male karyotype.
Table 3
Summary of siblingship testing; de-identiﬁed Genea021, Genea022 and Genea023 share
identical maternal and paternal lines and with variable locus analysis are likely related
as full siblings.
Result
Variable locus analysis SIVF021 and SIVF022 — full sibs inconclusive
SIVF021 and SIVF023 — full sibs practically proven
SIVF022 and SIVF023 — full sibs inconclusive
Y chromosome comparison No mismatches between the lines thus common
paternal lineage
Mitochondrial DNA analysis Identical mitochondrial sequences thus common
maternal line
Interpretation It is likely that all cell lines are related
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1. Karyotyping: passage 44 (42 on feeders, 2 enzymatic); for enrich-
ment of metaphase cells, cellular outgrowths were incubated with
either 0.22 ng/ml colcemid (Invitrogen) and 37.5 g/ml BrdU
(Sigma) for 17–19 h or 5 ng/ml colcemid for 2.5 h. Single cells were
subsequently obtained using Non-Enzymatic Cell Dissociation Solu-
tion (Sigma) and transferred to Sydney IVF's (nowGenea) diagnostic
cytogenetics laboratory for preparation of metaphase spreads and
cytogenetic analysis by G-banding. A minimum of 15 metaphase
cells were examined, of which a full karyotype or chromosome
counts were performed for 5 and 10 of the metaphases respectively.
2. Comparative Genomic Hybridisation (CGH) based chromosomal anal-
ysis: passage 12; CGH was used to screen targeted regions of theTable 1
CGH analysis summary; Genea021 (passage 12, 4 enzymatic) reporting a Trisomy 21 af-
fected male cell line.
CGH summary
Sample name Genea021p12_TE4
Date reported 8th October 2012
Hybridisation balance Balanced hybridisation was observed for chromosomes
1–20, 22 and sex chromosomes, relative to reference
DNA.
Unbalanced hybridisation was observed for chromosome
21, relative to reference DNA.
Copy number change Gain, chromosome 21, approximately 32,605 Kb
Interpretation ABNORMAL — male, trisomy 21
Table 2
STR proﬁle; Genea021 (passage 8) demonstrating male allele pattern and trisomy at D21S11.
D8S1179 D21S11 D7S820 CSF1PO D3S1358 TH01 D13S31
SIVF021p8 13, 14 29, 30, 32.2 11, 13 11, 13 15 6, 9.3 11, 12genome for gains and losses associatedwith chromosomal imbalances
such as aneuploidy, deletions and duplications. CGH was performed
using SurePrint G3microarrays (8× 60K format)whichwere scanned
with the Agilent Scanner C and analysed using the Genomic Work-
bench Standard Edition 5.0 software (Agilent Technologies).
3. DNA proﬁling: passage 8; DNA ‘ﬁngerprinting’ was performed using
the AmpFLSTR Identiﬁler PCR Ampliﬁcation Kit (Applied Biosystems
#4322288) to provide permanent genetic identiﬁcation of the cell
lines. https://www.thermoﬁsher.com/order/catalog/product/4322288
4. Siblingship testing: due to the de-identifying of embryos the
siblingship of Genea021, Genea022 and Genea023 was tested at
DNA Labs (a subsidiary of Sydney IVF; Sydney, Australia) via analysis
of 15 highly variable loci, 15 variable Y chromosome loci and mito-
chondrial DNA sequences in the D-loop HVRI and HVRII regions.
Pluripotency assessment
1. Immunoﬂuorescence: passage 10 (8 on feeders, 2 enzymatic); cells
were ﬁxed with formalin and stained with Nanog #560483 1:200;
Oct4 #560217 1:150: Tra1–60 #560121 1:150; SSEA4 #560308
1:200 (all BD Pharmingen). Images were acquired with an IN Cell
Analyser 6000 and quantiﬁed using an In Cell Developer Software
(GE).
2. Pluritest: passage 12 (8 on feeders, 4 enzymatic); RNA was collected
and subjected to a Pluritest, a bioinformatic assay of Pluripotency in
human cells based on gene expression proﬁles (Müller et al., 2012)
3. Alkaline Phosphatase: Passage 14; Genea021 grown on feeders was
stained as per manufacturers protocol using the Merck Millipore Al-
kaline Phosphatase Detection Kit (SCR004).
4. Teratoma formation: Passage 33; stem cells were received one day
prior to injection. On the day of injection cells were harvested by
manual scraping, washed and resuspended in DMEM/20%KSR for in-
tramuscular injection of cells into the left inner thigh muscle of the
hind leg. Approximately 1–2 × 106 cells (1xT25) in 50 μL were
injected per mouse at one site only. Resultant teratomas were ex-
cised, ﬁxed, sectioned and stained for assessment of tissues from
each of the embryonic germ layers.
Sterility testing
1. Mycoplasma: Passage 36; testing was performed at the Victorian In-
fectious Diseases Reference Laboratory using Mycoplasma Genus
PCR.
2. Microbial contamination: testingwas performed in conjunctionwith
our QC measures. Cells were thawed and cultured in 7 mL antibiotic7 D16S539 D2S1338 D19S433 vWA TPOX D18S51 D5S818 FGA
11, 13 17, 24 14.2, 15 14, 18 8, 11 13, 19 11, 12 22, 24
Fig. 2.Pluripotency validation ofGenea021. A) Immunoﬂuorescent staining (10×)of pluripotent cellmarkers SSEA4 (green),Nanog (red), Oct3/4 (green) and Tra1/60 (red), (passage 10, 2
enzymatic). B) Quantitation of expression of pluripotent markers. C) Pluritest Pluripotency (left) and Novelty (right) scores with Genea021 (passage 12, 4 enzymatic) outlined in black.
D) Tri-lineage teratoma formation (passage 33) with neuroepithelium, pigmented neuroepithelium, fat, primitive mesenchyme, bone and immature epithelium.
403B. Dumevska et al. / Stem Cell Research 16 (2016) 401–404free medium (Genea Biocells M2 medium) for 2–3 days at 37 °C. A
clear solution at ~48–72 h indicated lack of bacterial, fungal or
yeast contamination. Clarity of the solution was assessed by the
Cell Production Team.
Veriﬁcation and authentication
Ethics/consents
Karyotyped embryo cells were fully consented for development of
stem cells by all responsible people through an informed consent process
(signed de-identiﬁed consent form can be provided upon request). Do-
nors have received no payment of other beneﬁts for their donation. Do-
nated embryos originally created by assisted reproduction technology
(ART) for the purpose of procreation. Embryos were identiﬁed as unsuit-
able for implantation, biopsy or freezing due to abnormal development.
Embryonic outgrowths were developed for consented clinical investiga-
tion studies. Results of the studies have been reported back to the patient.
PGD analysis conclusion
Karyotype showed: 47, XY,+21— Trisomy 21male, consistent with
Down Syndrome.
Morphology
The derived stem cell line, Genea021, morphologically displays ad-
herent monolayer of compact cells in well-deﬁned colonies with high
nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 1A).Genetic analysis
The cell line has been karyotyped (Fig. 1B, Supplementary Fig. 1) and
also tested by CGH (Table 1, Supplementary Fig. 2), demonstrated 47,
XY karyotype consistent with original derivation and pre-implantation
genetic diagnosis (PGD). Analysis of STRmarkers showed Allele pattern
consistent with Trisomy 21 male genotype (Table 2, Supplementary
Fig.3). Siblingship analysis showed Genea021 to be siblings with
Genea022 and Genea023 (Table 3, Supplementary Fig. 4).
Pluripotency
GENEA021 is pluripotent by:
1. Alkaline Phosphatase stain positivity (Fig. 1A);
2. Immunoﬂuorescence with 71% Nanog positive, 84% Oct4, 23% Tra1–
60 and 95% SSEA4 positive (Fig. 2A, quantiﬁed in 2B);
3. Pluritest with a Pluripotency score of 21.85 and Novelty score of 1.42
(Fig. 2C); and
4. Teratoma formation which contained tissues derived from each of
the embryonic germ layers: endoderm, mesoderm, and ectoderm
(Fig. 2D).
Sterility
The cell line is tested and found negative for Mycoplasma and any
visible contamination (Supplementary Fig. 5).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.scr.2016.02.010.
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